278 related articles for article (PubMed ID: 34972978)
21. A review of neurotoxicities associated with immunotherapy and a framework for evaluation.
Burton LB; Eskian M; Guidon AC; Reynolds KL
Neurooncol Adv; 2021 Nov; 3(Suppl 5):v108-v120. PubMed ID: 34859238
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z; Zhang C; Zhou L; Dong P; Shi L
Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
[TBL] [Abstract][Full Text] [Related]
23. Neurotoxicity Biology and Management.
Danish H; Santomasso BD
Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
[TBL] [Abstract][Full Text] [Related]
24. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
25. Neurologic Complications of Cancer Therapies.
Lee EQ
Curr Neurol Neurosci Rep; 2021 Nov; 21(12):66. PubMed ID: 34817688
[TBL] [Abstract][Full Text] [Related]
26. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
27. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
28. Rheumatic immune-related adverse events from cancer immunotherapy.
Calabrese LH; Calabrese C; Cappelli LC
Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
[TBL] [Abstract][Full Text] [Related]
29. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy-Mediated Luminal Gastrointestinal Toxicities.
Thomas AS; Wang Y
Adv Exp Med Biol; 2021; 1342():331-337. PubMed ID: 34972972
[TBL] [Abstract][Full Text] [Related]
31. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
32. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
[TBL] [Abstract][Full Text] [Related]
33. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
34. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
35. Neurologic Toxicities of Cancer Immunotherapies: a Review.
Harrison RA; Tummala S; de Groot J
Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
[TBL] [Abstract][Full Text] [Related]
36. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Klein BA; Alves FA; de Santana Rodrigues Velho J; Vacharotayangul P; Hanna GJ; LeBoeuf NR; Shazib MA; Villa A; Woo SB; Sroussi H; Sonis S; Treister NS
Oral Dis; 2022 Jan; 28(1):9-22. PubMed ID: 34265157
[TBL] [Abstract][Full Text] [Related]
37. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
[TBL] [Abstract][Full Text] [Related]
38. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
39. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
40. Managing therapy-associated neurotoxicity in children with ALL.
Bhojwani D; Bansal R; Wayne AS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):376-383. PubMed ID: 34889354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
